Pediatric Antibiotic Use Associated With Respiratory Syncytial Virus and Influenza in the United States, 2008–2018
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiaf309 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Laura M King und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Epidemiology, School of Public Health, University of California, Berkeley, California, USA. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Influenza, Human, Anti-Bacterial Agents. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
Understanding the contributions of respiratory syncytial virus (RSV) and influenza infections to pediatric antibiotic use is limited. We aimed to estimate the proportions and incidence of outpatient antibiotic prescriptions associated with RSV and influenza infections in a sample of commercially insured US children.
Methods
We conducted a retrospective study of outpatient antibiotic prescriptions dispensed to children in the Optum Clinformatics DataMart from 2008 to 2018. We used negative binomial time series models regressing weekly antibiotic prescriptions against RSV and influenza circulation measures to estimate counterfactual rates of antibiotic prescriptions in the presence and absence of RSV and influenza circulation overall and by age group, census division, and antibiotic class. We considered syndromic RSV and influenza measures (medical claims) and laboratory measures (National Respiratory and Enteric Virus Surveillance System) and controlled for age, division, 13-valent pneumococcal conjugate vaccine introduction, and seasonal and secular trends.
Results
An estimated 6.3% (95% CI, 5.2%–7.3%) and 3.4% (3.1%–3.8%) of antibiotic prescriptions were associated with RSV and influenza, respectively. These estimates translate to 72.6 (59.7–85.9) RSV-associated and 40.0 (35.1–45.1) influenza-associated antibiotic prescriptions per 1000 children annually. RSV-associated antibiotic prescription incidence was highest among children aged ≤5 years while influenza-associated antibiotic prescriptions were highest among children >5 years. Macrolides were the antibiotic class for which RSV and influenza accounted for the greatest share of prescribing.
Conclusions
RSV and influenza are associated with meaningful proportions of pediatric antibiotic prescriptions. Measures to prevent RSV and influenza infections in children, including immunization, may reduce antibiotic use and aid in mitigating antibiotic resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Epidemiology, School of Public Health, University of California, Berkeley, California, USA.
- Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Alabama, USA.
- Kaiser Permanente Department of Research & Evaluation Southern California, Pasadena, California, USA.
ORCID-Profile: Laura M King, Katia J Bruxvoort
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
King, L. M., Bruxvoort, K. J., Tartof, S. Y., & Lewnard, J. A. (2025). Pediatric Antibiotic Use Associated With Respiratory Syncytial Virus and Influenza in the United States, 2008–2018. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf309
Vancouver
King LM, Bruxvoort KJ, Tartof SY, Lewnard JA. Pediatric Antibiotic Use Associated With Respiratory Syncytial Virus and Influenza in the United States, 2008–2018. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf309
BibTeX
@article{King2025,
author = {King, Laura M and Bruxvoort, Katia J and Tartof, Sara Y and Lewnard, Joseph A},
title = {Pediatric Antibiotic Use Associated With Respiratory Syncytial Virus and Influenza in the United States, 2008–2018},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiaf309}
}
EUVIMED